Skip to main content

Betamethasone / calcipotriene topical Side Effects

Medically reviewed by Philip Thornton, DipPharm. Last updated on Jul 5, 2023.

Applies to betamethasone/calcipotriene topical: topical application cream, topical application foam, topical application ointment, topical application suspension.

Serious side effects

Along with its needed effects, betamethasone/calcipotriene topical may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking betamethasone / calcipotriene topical:

Less common

  • Burning, itching, and pain in hairy areas
  • burning sensation of the skin
  • flushing or redness of the skin
  • itching skin
  • pus at the root of the hair
  • red, scaling, or crusted skin
  • scaly rash
  • skin irritation
  • thinning of the skin with easy bruising
  • unusually warm skin


  • Body aches or pain
  • chills
  • cough
  • darkening of the skin
  • diarrhea
  • difficulty with breathing
  • ear congestion
  • fever
  • general feeling of discomfort or illness
  • headache
  • joint pain
  • lightening of normal skin color
  • lightening of the treated areas of dark skin
  • loss of appetite
  • loss of voice
  • muscle aches and pains
  • nausea
  • raised, dark red, or wart-like spots on the skin
  • red, sore eyes
  • shivering
  • sneezing
  • sore throat
  • spots on your skin that look like a blister or pimple
  • stuffy or runny nose
  • sweating
  • trouble sleeping
  • unusual tiredness or weakness
  • vomiting
  • worsening of psoriasis

Incidence not known

  • Blindness
  • blurred vision
  • burning and itching of the skin with pinhead-sized red blisters
  • decreased vision
  • eye pain
  • tearing

Other side effects

Some side effects of betamethasone / calcipotriene topical may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

  • Bruising
  • large, flat, blue, or purplish patches in the skin
  • pain


Incidence not known

  • Dryness of the skin
  • reddish purple lines on the arms, face, legs, trunk, or groin
  • redness and scaling around the mouth

For Healthcare Professionals

Applies to betamethasone / calcipotriene topical: topical cream, topical foam, topical ointment, topical suspension.


Very common (10% or more): Pruritus (17%)

Common (1% to 10%): Skin exfoliation

Uncommon (0.1% to 1%): Skin infection, folliculitis, skin atrophy, exacerbation of psoriasis, dermatitis, erythema, rash (e.g., exfoliative, papular, pustular), purpura, ecchymosis, skin burning sensation, skin irritation

Rare (less than 0.1%): Furuncle, pustular psoriasis, skin striae, photosensitivity reaction, acne, dry skin[Ref]

Nervous system

Very common (10% or more): Headache (16%)[Ref]


Rare (less than 0.1%): Hypercalcemia, hyperglycemia[Ref]


Very common (10% or more): Adrenal suppression (15%)

Rare (less than 0.1%): Cushing's syndrome[Ref]


Rare (less than 0.1%): Hypersensitivity[Ref]


Very common (10% or more): Nasopharyngitis (11%)

Common (1% to 10%): Upper respiratory tract infection[Ref]


Uncommon (0.1% to 1%): Application site pigmentation changes, application site pain/burning[Ref]


Frequency not reported: Vision blurred[Ref]

Frequently asked questions


1. Product Information. Taclonex (betamethasone-calcipotriene topical). Leo Pharma Inc. 2022.

2. Product Information. Enstilar (betamethasone-calcipotriene topical). Leo Pharma Inc. 2022.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.